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(-33.55±50.89 g/L, p value=0.035), which was not seen in placebo
group (16.57±214.67 g/L, p value=0.794).
Conclusion: Dapagliflozin demonstrated greater benefit in reduc-
tion of Lp(a), particularly in patients with higher baseline Lp (a) of
N 30g/L. This observation may provide a possible explanation on the
CV benefit of SGLT-2 in these high-risk patients.
doi:10.1016/j.ijcard.2018.11.060
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Background: Physicians in tertiary centers face a constant
challenge in selecting patient with ADHF to be admitted from district
healthcare centre, especially with limited resources. Appropriate risk
stratification of patients with ADHF would improve the efficiency of
our healthcare delivery system.
Objective: We aim to find potential relationship between Killip
clinical scoring with clinical outcome of ADHF, including in-patient
mortality and requirement of advanced cardiorespiratory support.
Methods: 35 consecutive cases with a discharge diagnosis of
ADHF and admission creatinine clearance of more than 30 were
randomly reviewed. Cases were analyzed retrospectively for their
Killip score, in-patient mortality, requirement of advance cardiore-
spiratory care or ICU admission.
Results: There were 21 male patients (60%) and 14 female
patients. Mean age was 61±19 years old. Mean duration of ward-
stay was 6±4 days. Comorbidities were 14 (40%) with history of
coronary artery diseases and 17 (49%) with diabetes mellitus. 15
patients (43%) were on at least a single type of guideline directed
medication for heart failure. The cohort was almost evenly distributed
between thosewith aKillip score of 2 and above 2. A Killip score of 3 and
above was found to have good positive predictive value (87%) for
advanced cardio-respiratory care and negative predictive value of 78%.
No in-patient death was observed for the group with Killip 2 while
5 deaths were recorded in the group scoringmore than 2. A Killip score
of 3 had excellent (100%) negative predictive value for in-patient
mortality but poor positive predictive value (33%). Significant relation-
ship (pb0.001) was observed for Killip scoring on both outcomes.
Conclusion: Killip scoring may be useful for on-call physician to
decide the need on tertiary care among patient with ADHF and
mortality outcome. However, more prospective studies and patients
should be recruited to validate the study.
doi:10.1016/j.ijcard.2018.11.061
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Background: Heart failure (HF) remains an important cause
of morbidity and mortality. HF experts have classified HF into
3 distinct groups based on left ventricular ejection fraction (LVEF);
HF with reduced EF (HFrEF), HF with mid-range EF (HFmrEF) and HF
with preserved EF (HFpEF).
Objective: To compare characteristics and predictive factors for
in-hospital mortality amongst HFpEF / HFmrEF vs HFrEF patients
presented with acute decompensated HF (ADHF) to lnstitut Jantung
Negara (IJN).
Methods: A retrospective observational analysis of ADHF patient's
first admission from 2009 to 2015, using descriptive, cross tabulation,
univariate and multivariate logistic regression analysis. Groups were
compared using non-parametric test (Mann-Whitney U test). ROC
curve was used to determine cut off for variables of interest.
Results:Of 2439 ADHFpatients, 28% hadHFpEF/HFmrEF, 72%HFrEF.
Compared with HFrEF, HFpEF/HFmrEF patients were older (60.6 vs
67.3years), more commonly female (20.4 vs 45.8%), more likely to have
renal insufficiency (24.9 vs 29.7%), atrial fibrillation (17 vs 31.9%), but
less likely to have coronary artery disease (CAD) (71.2 vs 64.3%),
previous myocardial infarction (30.3 vs 16.7%). At presentation, HFpEF/
HFmrEF patients had higher systolic blood pressure (SBP) but lower
heart rate (HR) (140.5 vs 122 mmHg; 78 vs 87 bpm), NT-proBNP
(3179.0 vs 6767.5 pg/ml) and uric acid (465 vs 527 μmol/L). In-hospital
mortalities were lower in HFpEF/HFmrEF patients (2.3 vs 5.5%). In
multivariate analysis, HFpEF/HFmrEF patients fared poorly if their SBP
were ≤ 100mm Hg (OR9.216, p0.001) or urea N 7mmol/L (OR16.494,
p0.008). Amongst HFrEF, mortalities were higher if they had atrial
fibrillation (OR2.162, p0.025), history of stroke (OR2.99, p0.028),
eGFR b 40 ml/min/1.73m2 (OR2.215, p0.02), NT-proBNP ≥ 15000
(OR2 .534, p0.005), sodium b 135mmol/L (OR2.575, p0.002), positive
Troponin T (OR2.656, p0.002). Having 2 or 3 disease-modifying heart
failure medications conferred lower mortality (OR0.191, pb0.001;
OR0.109, pb0.001) in HFrEF but not in HFpEF/HFmrEF. Interestingly
background hypertension showed lower mortality in both HFpEF/
HFmrEF (OR 0.19, p0.006) and HFrEF (OR0.37, p0.003).
Conclusion: Majority of ADHF presentations were from the HFrEF
group. In-hospital mortalities were lower in HFpEF/HFmrEF group.
Independent predictors for in-hospital mortalities amongst HFpEF/
HFmrEF are limited, proving this group to be challenging. Further
studies are needed to understand the complexity of this group.
doi:10.1016/j.ijcard.2018.11.062
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Background: Heart failure (HF) is associated with high mortality
and morbidity with frequent hospital readmissions and multiple
emergency unit visits. In the HF Clinic in Sarawak Heart Center
(SHC), pharmacist's intervention was considered an essential
element in the multidisciplinary team. At HF clinic, a dedicated
clinical pharmacist reviewed patients' medications and provided
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